logo
logo
Sign in

The Growing Need For More Effective Vaccines To Drive Disease Eradication Efforts Opens New Avenues For Intramuscular Vaccine Adjuvants Market

avatar
Gauri Cmi
The Growing Need For More Effective Vaccines To Drive Disease Eradication Efforts Opens New Avenues For Intramuscular Vaccine Adjuvants Market



The Intramuscular Vaccine Adjuvants Market is estimated to be valued at US$ 694.19 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Intramuscular vaccine adjuvants are substances that are added to vaccines to boost immune response, allowing for lower vaccine doses and offering longer lasting protection. They stimulate innate immunity and enable the development of a stronger adaptive immune response to vaccines. Some key types of intramuscular vaccine adjuvants include aluminum salts, liposomes, oil-in-water emulsions, and others. They are commonly used in vaccines for diseases such as influenza, hepatitis A & B, HPV, and others. Growing immunization efforts globally are expected to drive demand for more effective vaccines and adjuvants.

Market Dynamics:

Rising incidence of infectious diseases is expected to be a major driver for the intramuscular vaccine adjuvants market over the forecast period. According to the World Health Organization (WHO), infectious diseases account for around 26% of global disease burden. New viruses are also emerging at an alarming rate requiring improved vaccines. Furthermore, adjuvants allow for lowered vaccine doses which aids mass immunization programs. This is important given budget constraints in developing economies for immunization. Difficulties in developing effective vaccines for complex diseases such as HIV, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) has led researchers to focus on adjuvants to enhance vaccine immunogenicity. This will further support market growth.

Segment Analysis

The Global Intramuscular Vaccine Adjuvants Market is dominated by the adjuvants sub-segment. Adjuvants are essential components added to some vaccines to boost the immune response and produce more antibodies and longer-lasting immunity. Popular adjuvant formulations include aluminum salts, oil-in-water emulsions, liposomes and nanoparticles. Aluminum salts have been widely used as adjuvants in licensed human vaccines. They are attractive for their availability and low cost. Newer compounds like oil-in-water emulsions and liposomes are gaining prominence due to better immune response generation.

PEST Analysis

Political: Government support for vaccine research and production has increased significantly after the COVID pandemic. More funds are flowing towards adjuvant development to strengthen vaccine efficacy.

Economic: The rising incidence of chronic diseases and infectious outbreaks is driving demand for effective vaccines. This represents an opportunity for adjuvant producers to penetrate new disease markets and increase sales volumes.

Social: Increased public awareness about vaccine-preventable diseases is driving demand for vaccination programs. However, hesitancy still exists regarding newer adjuvanted vaccines due to unknown safety and efficacy profiles.

Technological: Biotechnology and materials science advances are enabling the design of novel adjuvant formulations with tailored immune stimulatory properties. Liposomes, nanoparticles and toll-like receptor agonists show promise as next-gen vaccine boosters.

Key Takeaways

The global intramuscular vaccine adjuvants market is expected to witness high growth, exhibiting CAGR of 6.7% over the forecast period, due to increasing demand for vaccines to tackle emerging infectious diseases. The market size for 2023 is estimated at US$ 694.19 Mn.

North America dominates the global intramuscular vaccine adjuvants market currently owing to robust biologics R&D and manufacturing base. Presence of major adjuvants producers in the US and Canada and high healthcare expenditures have propelled the regional market. Asia Pacific is expected to be the fastest growing market going forward due to rising vaccination rollout, increasing government emphasis on immunization programs and growing biopharma industry in China and India.

Key players operating in the intramuscular vaccine adjuvants market include Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc., CSL Limited, OZ Biosciences. Major players are focused on developing proprietary adjuvant-antigen formulations for various infectious diseases and cancers through collaborations and acquisitions.

 

Read More: https://www.rapidwebwire.com/intramuscular-vaccine-adjuvants-market-analysis/


collect
0
avatar
Gauri Cmi
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more